Loading...
Pharmaceutical Importer · United States · Nutritional Supplements Focus · $6.0M Total Trade · DGFT Verified
Aurologistic Llc,(auromedics Pharma is a pharmaceutical importer based in United States with a total trade value of $6.0M across 3 products in 3 therapeutic categories. Based on 121 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments.
Aurologistic Llc,(auromedics Pharma imports across 3 therapeutic categories, with Nutritional Supplements (56.2%), Gastrointestinal (38.0%), Advanced Antibiotics (5.8%) representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.
Nutritional Supplements
1 products · 56.2% · $3.4M
Gastrointestinal
1 products · 38.0% · $2.3M
Advanced Antibiotics
1 products · 5.8% · $350.0K
| # | Product | Category | Value | Ships | Share | Rk |
|---|---|---|---|---|---|---|
| 1 | Sodium | Nutritional Supplements | $3.4M | 68 | 0.9% | 6 |
| 2 | Pantoprazole | Gastrointestinal | $2.3M | 46 | 0.2% | 10 |
Company type, headquarters, distribution network, and industry role
Aurologistic LLC, operating under the trade name Auromedics Pharma, is a pharmaceutical importer and buyer based in the United States. The company specializes in sourcing finished pharmaceutical formulations—including tablets, capsules, syrups, and injections—from India. Headquartered in East Windsor, New Jersey, Auromedics Pharma plays a pivotal role in the U.S. pharmaceutical distribution network by facilitating the importation and distribution of these formulations to various stakeholders within the healthcare sector.
As a dedicated importer, Auromedics Pharma focuses exclusively on finished dosage forms, ensuring that the products meet the stringent regulatory standards required for sale and distribution in the U.S. market. This specialization allows the company to maintain a streamlined supply chain, emphasizing quality control and compliance with U.S. Food and Drug Administration (FDA) regulations. By sourcing products from India, Auromedics Pharma leverages the country's robust pharmaceutical manufacturing capabilities, which are recognized for producing high-quality generics that are both cost-effective and reliable.
Auromedics Pharma's distribution network is strategically designed to ensure efficient delivery of pharmaceutical products across the United States. While specific warehouse locations are not publicly disclosed, the company operates from its headquarters in East Windsor, New Jersey, positioning itself advantageously for nationwide distribution. The logistics capabilities are tailored to handle the complexities of pharmaceutical imports, including compliance with FDA regulations, temperature-controlled storage requirements, and timely delivery schedules. This infrastructure supports the company's commitment to maintaining the integrity and quality of the imported products throughout the distribution process.
| 3 |
| Piperacillin |
| Advanced Antibiotics |
| $350.0K |
| 7 |
| 0.4% |
| 12 |
Aurologistic Llc,(auromedics Pharma imports 3 pharmaceutical products across 3 categories into United States totaling $6.0M.
Shipment-level records, supplier connections & pricing for Aurologistic Llc,(auromedics Pharma.
Request DemoGeographically, Auromedics Pharma's coverage spans the entire U.S., ensuring that healthcare providers, pharmacies, and hospitals have access to the imported formulations. The company's logistics operations are designed to accommodate the diverse needs of the U.S. healthcare system, including bulk shipments to large institutions and smaller deliveries to regional pharmacies. By maintaining a flexible and responsive distribution network, Auromedics Pharma effectively meets the demands of the U.S. pharmaceutical market.
In the U.S. pharmaceutical supply chain, Auromedics Pharma functions primarily as a pharmaceutical importer and distributor. The company sources finished pharmaceutical formulations from Indian manufacturers and imports them into the United States, where they are distributed to various healthcare providers, including hospitals, clinics, and pharmacies. This role is crucial in ensuring the availability of cost-effective and high-quality generic medications within the U.S. market.
By focusing on finished dosage forms, Auromedics Pharma differentiates itself from other entities that may import raw active pharmaceutical ingredients (APIs) or bulk drugs. This specialization allows the company to concentrate on the complexities associated with the importation and distribution of ready-to-use pharmaceutical products, including compliance with FDA regulations, quality assurance, and logistical coordination. Through this dedicated approach, Auromedics Pharma contributes to the diversification and stability of the U.S. pharmaceutical supply chain, offering healthcare providers access to a broader range of therapeutic options.
Sourcing concentration, supply chain resilience, and strategic implications
Auromedics Pharma's sourcing strategy is characterized by a significant concentration on a limited number of products imported from India. The company's total import value from India amounts to $6.0 million USD, encompassing 121 shipments of three distinct products across three therapeutic categories. This indicates a focused approach to product selection, potentially streamlining operations and quality control processes.
The top three products imported are Sodium ($3.4 million, Rank #6, 0.9% share), Pantoprazole ($2.3 million, Rank #10, 0.2% share), and Piperacillin ($350,000, Rank #12, 0.4% share). These products fall into the therapeutic categories of Nutritional Supplements (56.2%), Gastrointestinal (38.0%), and Advanced Antibiotics (5.8%), respectively. The high concentration on these specific products suggests a strategic choice to focus on areas with established demand and expertise.
While this sourcing concentration may offer operational efficiencies, it also presents potential risks. Dependence on a narrow product range could expose Auromedics Pharma to market fluctuations and regulatory changes affecting these specific products. Additionally, any supply chain disruptions with Indian manufacturers could significantly impact the company's ability to meet U.S. market demands. Therefore, it is essential for Auromedics Pharma to continuously assess and manage these risks to maintain a resilient and responsive supply chain.
Auromedics Pharma's supply chain resilience is closely tied to its sourcing strategy from Indian manufacturers. The company's focus on a limited number of products necessitates a deep integration with its suppliers to ensure consistent quality and timely delivery. However, this concentrated sourcing approach may expose the company to risks associated with supply chain disruptions, such as manufacturing delays, quality control issues, or geopolitical factors affecting trade between the U.S. and India.
To mitigate these risks, it is crucial for Auromedics Pharma to establish robust relationships with its Indian suppliers, ensuring that they adhere to Good Manufacturing Practices (GMP) and maintain high-quality standards. Diversifying the supplier base and incorporating backup suppliers can also enhance supply chain resilience. Additionally, implementing comprehensive risk management strategies, including regular audits and contingency planning, will be essential for maintaining a stable and reliable supply chain.
Auromedics Pharma's concentrated sourcing pattern positions the company to leverage its expertise in specific therapeutic areas, potentially enhancing its competitive edge in the U.S. market. By focusing on products with established demand, the company can streamline operations and build strong relationships with healthcare providers seeking reliable sources for these medications.
For Indian exporters, this sourcing pattern presents both opportunities and challenges. Suppliers that can consistently meet the quality and regulatory standards required by Auromedics Pharma may find a stable and lucrative market for their products. However, the limited product range and high dependency on specific therapeutic categories mean that Indian exporters must be prepared to adapt to the evolving needs and preferences of the U.S. market. Flexibility and responsiveness to market demands will be key to establishing and maintaining successful partnerships with Auromedics Pharma.
Regulatory authority, GMP requirements, import licensing for United States
In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation, approval, and distribution of pharmaceutical products. The FDA enforces a comprehensive framework of regulations designed to ensure the safety, efficacy, and quality of drugs available in the U.S. market.
Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act (FDCA), which provides the legal foundation for the FDA's authority over drug products. The Drug Approval Process, as outlined by the FDA, involves rigorous evaluation of clinical data, manufacturing practices, and labeling to ensure compliance with established standards. For foreign manufacturers, including those in India, obtaining FDA approval is a critical step in entering the U.S. market, necessitating adherence to FDA guidelines and inspections.
Import licensing requirements for pharmaceutical products entering the United States are stringent. Foreign manufacturers must register their facilities with the FDA and obtain an Establishment Registration number. Additionally, they must list their drug products with the FDA, providing detailed information about each product's composition, labeling, and intended use. Compliance with Good Manufacturing Practices (GMP) is mandatory, ensuring that products are consistently produced and controlled according to quality standards.
The FDA recognizes GMP certifications from reputable international bodies, including the European Union's EU GMP, the World Health Organization's WHO GMP, and the Pharmaceutical Inspection Co-operation Scheme's PIC/S. These certifications facilitate the acceptance of foreign products into the U.S. market, provided that the manufacturing processes meet the FDA's rigorous standards.
Pharmaceutical products imported into the United States must undergo batch testing to verify their identity, strength, quality, and purity. Stability studies are required to ensure that products maintain their quality throughout their shelf life under various storage conditions. Labeling must comply with FDA regulations, including accurate and comprehensive information about the product's ingredients, dosage instructions, indications, and potential side effects.
Labeling must be in English and include specific elements such as the drug's established name, dosage form, strength, and the name and address of the manufacturer. Serialization mandates, as part of the Drug Supply Chain Security Act (DSCSA), require unique identifiers on packaging to track and trace products through the supply chain, enhancing security and preventing counterfeit drugs from entering the market.
Between 2024 and 2026, several policy changes have impacted the importation of pharmaceutical products from India into the United States. The FDA has implemented stricter inspection protocols for foreign manufacturing facilities, leading to increased scrutiny of Indian suppliers. Additionally, there have been updates to the DSCSA, expanding serialization requirements to include more detailed tracking information. These changes aim to enhance drug safety and supply chain transparency but may pose challenges for Indian exporters in terms of compliance and operational adjustments.
Product strategy, sourcing profile, and market positioning
Auromedics Pharma's product strategy focuses on three primary therapeutic areas: Nutritional Supplements (56.2%), Gastrointestinal (38.0%), and Advanced Antibiotics (5.8%). This strategic focus aligns with market demands for essential medications in these categories, addressing prevalent
Aurologistic Llc,(auromedics Pharma imports 3 pharmaceutical products across 3 categories. Top imports: Sodium ($3.4M), Pantoprazole ($2.3M), Piperacillin ($350.0K).
Aurologistic Llc,(auromedics Pharma's total pharmaceutical import value from India is $6.0M, based on 121 verified shipments in Indian Customs (DGFT) data.
Aurologistic Llc,(auromedics Pharma imports across 3 categories. The largest: Nutritional Supplements (56.2%), Gastrointestinal (38.0%), Advanced Antibiotics (5.8%).
Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Verify import regulations and drug registration requirements with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3 Products Tracked
3 therapeutic categories
Expert-Reviewed
By pharmaceutical trade specialists
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.